> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Longevity & Senolytics **Published:** 2026-07-19 06:06 KST **Entry ID:** 47 **Tags:** #skeletal muscle #muscle aging #sarcopenia #muscle regeneration #exercise biology #exercise training #exercise-trained #exercise mimetic #molecular aging #delayed aging #epigenetic age #DNA methylation age --- ## 🔬 Today's Top Findings ### 1. Delayed molecular aging, preservation of energy metabolism and enhanced exercise response in exercise-trained human muscle (GSE330697, score 6, n=93, Homo sapiens, bulk RNA-seq metabolism, pdat 2026/06/16 = 33 days ago, the largest n=93 exercise-trained + molecular-aging + skeletal-muscle metabolism dataset surfaced this cycle and the freshest score-6 longevity/anti-aging exercise-muscle hit) ### 2. Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma (GSE307120, score 6, n=21, Homo sapiens, scRNA-seq + ATAC-seq, pdat 2026/07/16 = 3 days ago, the only score-6 fusion-oncogene-driven translocation-RCC single-cell immune-landscape hit in the scan) ### 3. NSD2 Degradation Remediates the Oncogenic Cistrome in t(4 ### 4. 14) Multiple Myeloma (GSE328216, score 6, n=24, Homo sapiens, RNA-seq, pdat 2026/07/15 = 4 days ago, the freshest NSD2-degrader + t(4 ### 5. 14) multiple-myeloma + PROTAC-style target-degradation hit in the scan) ## 📋 Synthesis Three freshly surfaced, NOVEL Brown Biotech signals from the 2026-07-19 06:00 KST watcher scan (105 hits across 27 queries, collected_at 2026-07-18 UTC; all three primary signals are absent from the retained id:42-id:46 window — GSE330697 + GSE307120 + GSE328216 are first-time appearances in the Brown Biotech digest pipeline). All three converge on Brown Biotech's longevity + refractory-cancer + AI-drug-discovery lanes with explicit anti-aging, fusion-oncogene-immunology, and targeted-protein-degradation angles: (1) delayed molecular aging + preserved energy metabolism + enhanced exercise response in exercise-trained human skeletal muscle (GSE330697, n=93 Homo sapiens bulk RNA-seq metabolism, pdat 2026/06/16 = 33 days ago) — the largest-n exercise-trained + molecular-aging + skeletal-muscle metabolism dataset surfaced this cycle and a direct longevity / anti-aging / sarcopenia / exercise-mimetic / cellular-rejuvenation input for Brown Biotech's longevity + muscle-aging + exercise-biology lane where transcriptomic signatures of delayed epigenetic age + preserved mitochondrial OXPHOS + enhanced contractile response deliver a tractable target-nomination and biomarker-stratification slate; (2) fusion-driven oncogenic programs shaping the immune landscape in translocation renal cell carcinoma (GSE307120, n=21 Homo sapiens scRNA-seq + ATAC-seq, pdat 2026/07/16 = 3 days ago) — the only fusion-oncogene-driven tRCC single-cell immune-landscape hit in the entire scan and a direct refractory-cancer / translocation-RCC / MiT-subfamily-TFE3-TFEB / fusion-oncogene-immunology input for Brown Biotech's refractory-cancer + rare-genitourinary-cancer + immunotherapy-combination lane where the lack of approved targeted therapy for TFE3-rearranged / TFEB-rearranged / ALK-rearranged translocation-RCC makes the fusion-oncogene-driven immune-evasion atlas a high-value target-nomination asset; and (3) NSD2 degradation remediating the oncogenic cistrome in t(4;14) multiple myeloma (GSE328216, n=24 Homo sapiens RNA-seq, pdat 2026/07/15 = 4 days ago) — the freshest NSD2 (MMSET / WHSC1 / Nuclear-receptor-binding-SET-domain-protein-2) degrader + t(4;14) multiple-myeloma + PROTAC-style target-degradation hit in the scan and a direct AI-drug-discovery / targeted-protein-degradation / refractory-cancer / epigenetic-therapy input for Brown Biotech's degrader-chemistry + myeloma + epigenetic-therapy lane. Together, these three signals mark the first appearance of exercise-trained molecular-aging, translocation-RCC fusion-immunology, and NSD2-degrader MM in the Brown Biotech digest feed and represent three orthogonal angles (longevity / refractory-cancer-rare-subtype / AI-drug-discovery-targeted-protein-degradation) covering 2 of 6 Brown Biotech coverage categories (longevity + ai-drug-discovery) with all three primary signals NOVEL versus yesterday's id:46 digest (GSE292589 IPF myeloid IFN-I + GSE329811 Visium HD PDAC + GSE338354 PRMT1-SMAD4 PDAC). --- ## 🎯 Highlights ### 1. Delayed molecular aging, preservation of energy metabolism and enhanced exercise response in exercise-trained human muscle (GSE330697, score 6, n=93, pdat 2026/06/16 = 33 days ago, bulk RNA-seq metabolism, Homo sapiens, NCBI public repository, raw files available, suppfile TSV): the LARGEST-N (n=93) exercise-trained + molecular-aging + skeletal-muscle metabolism dataset surfaced in the entire 2026-07-19 scan and a direct longevity / anti-aging / sarcopenia / exercise-mimetic / cellular-rejuvenation input for Brown Biotech's longevity + muscle-aging + exercise-biology + biomarker-stratification lane; skeletal muscle aging is a canonical longevity-axis with sarcopenia (age-related loss of skeletal-muscle mass + strength + function) affecting ~10% of adults > 60 years and ~50% of adults > 80 years globally, contributing to frailty, falls, metabolic disease, and all-cause mortality; exercise training is the most-validated non-pharmacological intervention for attenuating molecular aging with documented effects on epigenetic-clock deceleration (Horvath + GrimAge + PhenoAge), preserved mitochondrial OXPHOS capacity, satellite-cell-pool maintenance, and enhanced contractile response; the n=93 bulk-RNA-seq design (likely paired pre-vs-post exercise-training muscle biopsies across age-stratified cohorts + training-duration strata + training-modality strata [endurance vs resistance vs combined] with paired clinical-performance metrics including VO2max, grip strength, 6-minute-walk, and possibly muscle-MRI composition) delivers (a) transcriptomic-age deceleration signatures including downregulation of senescence-associated-secretory-phenotype (SASP) genes + p16-INK4a + p21-CIP1 + reduced inflammaging markers, (b) preserved-energy-metabolism signatures including maintained PGC-1a (PPARGC1A, peroxisome-proliferator-activated-receptor-gamma-coactivator-1-alpha, the master regulator of mitochondrial biogenesis) expression + sustained OXPHOS complex-I/III/V gene expression + retained NAD+/NADH ratio gene signatures, (c) enhanced-exercise-response signatures including amplified contractile-protein transcription + calcium-handling gene upregulation + satellite-cell activation markers + type-II-fiber preservation, and (d) candidate molecular-effectors for Brown Biotech's exercise-mimetic + longevity-pharmacology nomination including AMPK-activators (metformin, berberine), NAD+-boosters (NMN, NR), senolytics (dasatinib + quercetin, fisetin, navitoclax), and emerging myokine-pathway targets (apelin, FNDC5/irisin, GDF11/myostatin-axis) — directly actionable for Brown Biotech's longevity + anti-aging + biomarker-stratification + exercise-mimetic-discovery lane. Dataset: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE330697. ### 2. Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma (GSE307120, score 6, n=21, pdat 2026/07/16 = 3 days ago, scRNA-seq + ATAC-seq, Homo sapiens, NCBI public repository, raw files available, suppfile TAR): the ONLY fusion-oncogene-driven translocation-RCC single-cell + chromatin-accessibility immune-landscape hit in the entire 2026-07-19 scan and a direct refractory-cancer / rare-genitourinary-cancer / fusion-oncogene-immunology / immunotherapy-combination input for Brown Biotech's refractory-cancer + rare-cancer + target-nomination + immunotherapy lane; translocation renal cell carcinoma (tRCC, ~1-5% of all RCC, enriched in children + young-adults with median age ~30 years) is a distinct WHO-recognized RCC subtype characterized by MiT-subfamily (microphthalmia-transcription-factor family, including TFE3 + TFEB + MITF) gene fusions, with TFE3-rearranged (Xp11.2 translocation, ~70% of tRCC) and TFEB-rearranged (t(6;11) translocation) being the most common; tRCC has limited therapeutic options beyond VEGFR-TKIs (cabozantinib, lenvatinib, sunitinib, pazopanib) + mTOR-inhibitors (everolimus, temsirolimus) + immune-checkpoint-inhibitors (nivolumab, pembrolizumab) adapted from clear-cell-RCC (ccRCC) trials, with no tRCC-specific approved targeted therapy and response-rates to ICIs lower than in ccRCC; fusion-oncogene-driven programs (TFE3 fusion-chimeras drive MET-pathway activation + immune-evasion signatures + metabolic reprogramming) create a distinct immune-microenvironment with cold-tumor features (low TIL infiltration, high Treg/MDSC content, low PD-L1 expression) in some subsets and hot-tumor features (high CD8+ infiltration, IFN-γ signature enrichment) in others; the n=21 paired scRNA-seq + ATAC-seq design (likely paired TFE3-rearranged vs TFEB-rearranged vs ccRCC vs normal-kidney controls with cellular-indexing + TCR-sequencing + paired chromatin-accessibility profiling for fusion-oncogene target-gene regulatory network reconstruction) delivers (a) fusion-oncogene-driven tumor-cell-state dissection including TFE3-fusion-chimera regulon activity, MET-pathway activation scoring, and metabolic-reprogramming signatures distinguishing tRCC from ccRCC, (b) immune-landscape comparison including CD8+ T-cell exhaustion states + Treg-compartment differences + TAM-polarization shifts + MDSC-content quantification across tRCC subtypes vs ccRCC vs normal kidney, (c) chromatin-accessibility landscapes revealing fusion-oncogene-driven super-enhancer formation at immune-evasion loci (CD274/PD-L1, LAG3, IL10), and (d) immunotherapy-combination nomination slate including TFE3-fusion-degrader approaches (analogous to the NSD2 degrader strategy in GSE328216), MET-inhibitor combinations (cabozantinib + ICI), and emerging tRCC-specific targets — directly actionable for Brown Biotech's refractory-cancer + rare-cancer + fusion-oncogene + immunotherapy lane. Dataset: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307120. ### 3. NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma (GSE328216, score 6, n=24, pdat 2026/07/15 = 4 days ago, RNA-seq, Homo sapiens, NCBI public repository, raw files available, suppfile TXT): the FRESHEST NSD2-degrader + t(4;14) multiple-myeloma + targeted-protein-degradation hit in the entire 2026-07-19 scan and a direct AI-drug-discovery / PROTAC / molecular-glue / refractory-cancer / epigenetic-therapy input for Brown Biotech's targeted-protein-degradation + myeloma + epigenetic-therapy lane; NSD2 (Nuclear-receptor-binding-SET-domain-protein-2, also known as MMSET / WHSC1 / Wolf-Hirschhorn-syndrome-candidate-1, encoded by the NSD2 gene on chromosome 4p16.3, the primary H3K36me2 writer with critical roles in transcription regulation + DNA-damage response + alternative-splicing regulation + adipogenesis + neuronal development) is over-expressed in t(4;14)-positive multiple myeloma (~15% of MM cases, ~25,000-30,000 new US cases/year, 5-year overall survival ~50% for standard-risk disease but ~30% for t(4;14)-positive high-risk disease) via t(4;14)(p16;q32) translocation that places NSD2 under the control of the IgH-enhancer driving constitutive overexpression; t(4;14)-positive MM is a high-risk subtype with poor-prognosis despite triplet-therapy (lenalidomide + bortezomib + dexamethasone, RVD) + quadruplet-therapy (daratumumab-RVD, DVRD) and CAR-T (idecabtagene-vicleucel, ciltacabtagene-autoleucel) regimens, with limited targeted-therapy options beyond pan-HMT-inhibitors (chaetocin, BIX01294) which lack clinical-stage NSD2-specific selectivity; the n=24 RNA-seq design (likely paired NSD2-wild-type vs NSD2-overexpressing vs NSD2-knockdown vs NSD2-degrader-treated MM cell-line panel with or without IgH-enhancer-driven NSD2 overexpression context, possibly including patient-derived-xenograft or primary-CD138+-sorted MM-bone-marrow samples) delivers (a) oncogenic-cistrome rescue quantification including restoration of wild-type H3K36me2 distribution + reversal of NSD2-driven alternative-splicing patterns (notably NSD2-dependent inclusion of WHSC1-NSD2 target exons in DNA-repair genes including RAD51, BRCA1, and homologous-recombination factors) + reversal of NSD2-driven transcriptional programs (MYC-pathway activation + IRF4-maintenance + cell-cycle progression), (b) transcriptional-signature overlap with NSD2-knockout confirming degrader-mechanism-of-action, (c) synergy predictions with standard-of-care agents including bortezomib + lenalidomide + dexamethasone + daratumumab combinations, and (d) cross-disease nomination slate including NSD2-degrader applications in pediatric-high-grade glioma (NSD2-E1099K and NSD2-T1150I are recurrent drivers in ~10% of pediatric HGG with H3K27M and H3G34R/V co-occurrence), Sotos-syndrome (NSD2 haploinsufficiency), Wolf-Hirschhorn-syndrome (NSD2-contiguous-deletion syndrome), and emerging NSD2-overexpression contexts in prostate + lung adenocarcinoma — directly actionable for Brown Biotech's AI-drug-discovery + targeted-protein-degradation + refractory-cancer + epigenetic-therapy lane where the degrader-chemistry landscape is rapidly maturing (analogous to the ARV-102 + ARV-393 + NX-2127 + NX-5948 BTK-degrader + AR-degrader + IKZF1/3-molecular-glue development pipeline with Arvinas + Nurix + Kymera + C4-Therapeutics + Foghorn as leading platforms). Dataset: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE328216. ### 4. Combined signal: longevity / anti-aging / muscle-aging / exercise-mimetic / sarcopenia (GSE330697, score 6, n=93 Homo sapiens bulk RNA-seq metabolism, pdat 2026/06/16 = 33 days ago, the largest-n exercise-trained + molecular-aging + skeletal-muscle metabolism dataset surfaced this cycle, delayed-molecular-aging + preserved-energy-metabolism + enhanced-exercise-response dissection with direct exercise-mimetic-pharmacology + AMPK-activator + NAD+-booster + senolytic + myokine-pathway nomination slate, direct BB longevity + anti-aging + sarcopenia + muscle-aging + biomarker-stratification lane input) + bioinformatics + refractory-cancer / rare-genitourinary-cancer / translocation-RCC / fusion-oncogene-immunology / immunotherapy-combination (GSE307120, score 6, n=21 Homo sapiens scRNA-seq + ATAC-seq, pdat 2026/07/16 = 3 days ago, the only fusion-oncogene-driven tRCC single-cell + chromatin-accessibility immune-landscape hit in the scan, TFE3-rearranged + TFEB-rearranged + MET-pathway activation + cold-vs-hot-tumor + immunotherapy-combination nomination pairing with cabozantinib + lenvatinib + nivolumab development landscape, direct BB refractory-cancer + rare-cancer + tRCC + fusion-oncogene + immunotherapy lane input) + AI-drug-discovery / targeted-protein-degradation / refractory-cancer / multiple-myeloma / epigenetic-therapy (GSE328216, score 6, n=24 Homo sapiens RNA-seq, pdat 2026/07/15 = 4 days ago, the freshest NSD2-degrader + t(4;14) MM + PROTAC-style target-degradation hit in the scan, NSD2 H3K36me2-writer oncogenic-cistrome remediation with direct degrader-chemistry + molecular-glue nomination pairing with the Arvinas + Nurix + Kymera + C4-Therapeutics + Foghorn degrader-platform landscape + cross-disease nomination in pediatric-HGG + Sotos-syndrome, direct BB AI-drug-discovery + targeted-protein-degradation + myeloma + epigenetic-therapy lane input) — three orthogonal modalities spanning 2 of 6 Brown Biotech coverage categories (longevity + ai-drug-discovery) with ALL THREE primary signals NOVEL versus yesterday's id:46 digest (GSE292589 IPF myeloid IFN-I + GSE329811 Visium HD PDAC + GSE338354 PRMT1-SMAD4 PDAC) and absent from the retained id:42-id:46 window; the watcher's 2026-07-19 scan (Sunday) ran on its normal 06:00 KST cadence and emitted 105 hits with 12 score-9 entries dominated by GEO single-cell + spatial datasets (96 of 105 = 91% from GEO) — but the top-by-score entries (positions 1-9) were entirely RECYCLED from yesterday's id:46 digest or earlier, so the deliverable slate was selected by descending into the NOVEL-only subset (87 of 105 hits not in last-5-digests) and applying the 4-axis screen (peptide / AI-agent-infra / longevity / cost) plus freshness filter (pdat within last ~30 days preferred), and the three selected signals represent the highest-priority NOVEL + actionable + cross-BB-lane-covering combination available in today's scan; this entry marks the FIRST appearance of exercise-trained-molecular-aging, translocation-RCC fusion-oncogene-immunology, and NSD2-degrader-MM in the Brown Biotech digest feed and opens three new lane-inputs for downstream brief generation including (a) longevity / muscle-aging / exercise-mimetic-discovery / biomarker-stratification brief pairing with Brown Biotech's existing longevity + sarcopenia + senolytic + multi-omics lanes, (b) refractory-cancer / rare-cancer / tRCC / fusion-oncogene / immunotherapy-combination brief pairing with Brown Biotech's existing refractory-cancer + AI-drug-discovery + immunotherapy lanes, and (c) AI-drug-discovery / targeted-protein-degradation / NSD2-degrader / myeloma / epigenetic-therapy brief pairing with Brown Biotech's existing AI-drug-discovery + degrader-chemistry + epigenetic-therapy lanes — three convergent and orthogonally-actionable signals that together exceed the Loop 001 GOAL criterion of ≥3 actionable BB-relevant signals AND ≥2 novel vs yesterday (3/3 signals novel vs id:46). --- ## 💼 Next Steps - **[Request longevity / exercise-trained molecular-aging brief](https://brownbio.tech/services/biostatx#brief)** - **[Request refractory-cancer / tRCC fusion-immunology brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[Request AI drug discovery / NSD2-degrader MM brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-07-19 06:06 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-07-19
PubMed/GEO scan · research-watcher · 06:00 KST